Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.52 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.52 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.52 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.52 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.52 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.43 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.43 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.36 |
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.35 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HBB | P68871 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186191 | 0.98 | CYP3A4 (0.53) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| SCHEMBL14541701 | 0.98 | CYP3A4 (0.53) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| SCHEMBL14224817 | 0.98 | CYP3A4 (0.53) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| Acetic Acid SCHEMBL11356631 | 0.89 | ALDH1A1 (0.55) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| Pivalate SCHEMBL4575362 | 0.85 | ALDH1A1 (0.51) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| Mucic Acid SCHEMBL15509436 | 0.82 | ALDH1A1 (0.49) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1408231 | 0.81 | KMT2A (0.52) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| SCHEMBL9410650 | 0.80 | HTR2A (0.52) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| SCHEMBL14071918 | 0.80 | HTR2A (0.52) | KMT2AMEN1HBBCYP3A4CYP2D6 | |
| SCHEMBL7051224 | 0.80 | ADRA2C (0.52) | KMT2AMEN1HBBCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1636 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367139-A1 | COMPOUND HYDROCORTISONE AND NEOMYCIN SULFATE GRANULE AND PREPARATION METHOD THEREOF | HEBEI CHANGTIAN PHARMACEUTICAL CO LTD (CN) | 2025-12-04 | — | — | US | claimed |
| WO-2025100462-A1 | SOLID COMPOSITION CONTAINING BROMHEXINE | 第一三共ヘルスケア株式会社 | 2025-05-15 | — | — | WO | claimed |
| WO-2025009819-A1 | CUTTABLE AND CONSUMABLE TAPE-TYPE OR BAR-TYPE PREPARATION ENABLING DRUG DOSE CONTROL THROUGH LENGTH | 충북대학교 산학협력단 | 2025-01-09 | — | — | WO | claimed |
| CN-118362674-B | Feature spectrum of Kemin capsule and content detection method of various quality markers | 山东省中医药研究院 | 2024-10-01 | — | — | CN | claimed |
| CN-118362674-A | Feature spectrum of Kemin capsule and content detection method of various quality markers | 山东省中医药研究院 | 2024-07-19 | — | — | CN | claimed |
| CN-118252792-A | Compound paracetamol and guaifenesin oral solution and preparation method thereof | 海南倍特药业有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-114796280-B | Compound paracetamol and chlorphenamine maleate granules and preparation process thereof | 河北长天药业有限公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2023241662-A1 | COMPOUND PARACETAMOL AND CHLORPHENAMINE MALEATE GRANULE AND PROCESS FOR PREPARING SAME | 河北长天药业有限公司 | 2023-12-21 | — | — | WO | claimed |
| CN-115252814-A | Cyclodextrin-metal organic framework composition and preparation method thereof | 中国科学院上海药物研究所 | 2022-11-01 | — | — | CN | claimed |
| CN-110934833-B | Compound paracetamol and chlorphenamine maleate granules | 河北长天药业有限公司 | 2022-08-19 | — | — | CN | claimed |
| EP-1283703-A1 | RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR THE MANUFACTURE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2003-02-19 | — | — | EP | claimed |
| US-20020001617-A1 | Rapidly disintegrating tablet and process for the manufacture thereof | HANMI PHARM. CO., LTD. (KR) | 2002-01-03 | — | — | US | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001089485-A1 | RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR THE MANUFACTURE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2001-11-29 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0590382-B1 | Method to produce pellets containing an ephedrine derivative | NORDMARK ARZNEIMITTEL GMBH (DE) | 1996-07-24 | — | — | EP | claimed |
| US-5453280-A | Production of pellets composed of an ephedrine derivative | NORDMARK ARZNEIMITTEL GMBH (DE) | 1995-09-26 | — | — | US | claimed |
| EP-0590382-A1 | Method to produce pellets containing an ephedrine derivative | NORDMARK ARZNEIMITTEL GmbH. (DE) | 1994-04-06 | — | — | EP | claimed |